[SCHEDULE 13G/A] SI-BONE, Inc. SEC Filing
OrbiMed files Amendment No. 5 to a Schedule 13G/A reporting ownership in SI-BONE, Inc. (SIBN). OrbiMed Capital LLC reports beneficial ownership of 2,184,200 shares, representing 5.1% of SI-BONE's common stock, with sole voting and dispositive power over those shares. OrbiMed Advisors LLC reports beneficial ownership of 394,779 shares, representing 0.9%, with shared voting and dispositive power. Together the reporting persons hold 6.0% of the class on behalf of other persons and exercise investment and voting power through a management committee of three named members. The filing states the shares were acquired in the ordinary course of business and not for the purpose of changing control.
OrbiMed presenta l'Emendamento n. 5 al modulo Schedule 13G/A relativo alla partecipazione in SI-BONE, Inc. (SIBN). OrbiMed Capital LLC dichiara la titolarit脿 effettiva di 2.184.200 azioni, pari al 5,1% del capitale ordinario di SI-BONE, con pieno potere di voto e di disposizione su tali azioni. OrbiMed Advisors LLC segnala la titolarit脿 effettiva di 394.779 azioni, pari al 0,9%, con poteri di voto e disposizione condivisi. Insieme, i soggetti segnalanti detengono il 6,0% della classe per conto di altri e esercitano i poteri di investimento e di voto tramite un comitato di gestione composto da tre membri nominati. Nel deposito si afferma che le azioni sono state acquisite nell'ordinaria attivit脿 commerciale e non con l'intento di cambiare il controllo.
OrbiMed presenta la Enmienda n.潞 5 al Schedule 13G/A informando sobre su participaci贸n en SI-BONE, Inc. (SIBN). OrbiMed Capital LLC declara una propiedad beneficiaria de 2.184.200 acciones, lo que representa el 5,1% del capital social ordinario de SI-BONE, con poder exclusivo de voto y disposici贸n sobre esas acciones. OrbiMed Advisors LLC informa una propiedad beneficiaria de 394.779 acciones, equivalentes al 0,9%, con poder de voto y disposici贸n compartido. Juntos, los informantes poseen el 6,0% de la clase en nombre de otros y ejercen el poder de inversi贸n y voto a trav茅s de un comit茅 directivo formado por tres miembros nombrados. La presentaci贸n indica que las acciones se adquirieron en el curso ordinario del negocio y no con la finalidad de cambiar el control.
OrbiMed臧� SI-BONE, Inc. (SIBN) 歆�攵� 鞁犼碃毳� 鞙勴暣 Schedule 13G/A鞚� 靾橃爼靹�(Amendment No. 5)毳� 鞝滌稖頄堨姷雼堧嫟. OrbiMed Capital LLC電� 2,184,200欤茧ゼ 鞁れ 氤挫湢頃橁碃 鞛堨溂氅� 鞚措姅 SI-BONE 氤错喌欤检潣 5.1%鞐� 頃措嫻頃橁碃 頃措嫻 欤检嫕鞐� 雽�頃� 雼弲 鞚橁舶甓� 氚� 觳橂秳甓岇潉 氤挫湢頃滊嫟瓿� 氤搓碃頄堨姷雼堧嫟. OrbiMed Advisors LLC電� 394,779欤�, 歃� 0.9%毳� 鞁れ 氤挫湢頃橁碃 鞛堨溂氅� 鞚橁舶甓� 氚� 觳橂秳甓岇潉 瓿惦彊鞙茧 氤挫湢頃滊嫟瓿� 氤搓碃頄堨姷雼堧嫟. 氤搓碃鞛愲摛鞚� 頃╈硱靹� 頃措嫻 欤检嫕 韥措灅鞀れ潣 6.0%毳� 韮�鞚胳潉 雽�鞁犿暣 氤挫湢頃橁碃 鞛堨溂氅�, 歆�鞝曤悳 靹� 氇呾潣 鞙勳洂鞙茧 甑劚霅� 甏�毽渼鞗愴殞毳� 韱淀暣 韴瀽 氚� 鞚橁舶甓岇潉 頄夓偓頃╇媹雼�. 鞝滌稖靹滌棎電� 欤检嫕鞚� 鞝曥儊鞝侅澑 鞓侅梾 瓿检爼鞐愳劀 旆摑霅橃棃瓿� 歆�氚瓣秾 氤�瓴届潉 氇╈爜鞙茧 頃橃 鞎婌晿雼り碃 氇呾嫓霅橃柎 鞛堨姷雼堧嫟.
OrbiMed d茅pose l'Amendement n掳5 au Schedule 13G/A d茅clarant une participation dans SI-BONE, Inc. (SIBN). OrbiMed Capital LLC d茅clare la propri茅t茅 b茅n茅ficiaire de 2 184 200 actions, repr茅sentant 5,1% du capital ordinaire de SI-BONE, avec le pouvoir exclusif de vote et de disposition sur ces actions. OrbiMed Advisors LLC signale la propri茅t茅 b茅n茅ficiaire de 394 779 actions, soit 0,9%, avec des pouvoirs de vote et de disposition partag茅s. Ensemble, les personnes d茅clarante d茅tiennent 6,0% de la cat茅gorie au nom d'autres personnes et exercent le pouvoir d'investissement et de vote via un comit茅 de gestion compos茅 de trois membres nomm茅s. Le d茅p么t indique que les actions ont 茅t茅 acquises dans le cours normal des affaires et non dans le but de changer le contr么le.
OrbiMed reicht Nachtrag Nr. 5 zum Schedule 13G/A ein und meldet Beteiligung an SI-BONE, Inc. (SIBN). OrbiMed Capital LLC gibt an, wirtschaftlich 2.184.200 Aktien zu halten, was 5,1% des Stammkapitals von SI-BONE entspricht, und 眉ber diese Aktien alleinige Stimm- und Verf眉gungsgewalt zu besitzen. OrbiMed Advisors LLC meldet wirtschaftliches Eigentum an 394.779 Aktien, entsprechend 0,9%, mit geteilter Stimm- und Verf眉gungsgewalt. Zusammen halten die meldenden Personen 6,0% der Aktienklasse f眉r Dritte und 眉ben Anlage- und Stimmrechte durch ein Managementkomitee mit drei benannten Mitgliedern aus. In der Einreichung hei脽t es, die Aktien seien im gew枚hnlichen Gesch盲ftsverkehr erworben worden und nicht mit dem Ziel einer Macht眉bernahme.
- Material ownership disclosure: OrbiMed Capital reports a 5.1% stake (2,184,200 shares), triggering investor notice.
- Aggregate stake disclosed: Combined OrbiMed entities hold 6.0% of SI-BONE common stock on behalf of others.
- Clear control delineation: OrbiMed Capital has sole voting and dispositive power over its shares while OrbiMed Advisors reports shared power, clarifying governance roles.
- Acquisition context: Filing states holdings were acquired in the ordinary course of business and not to change control.
- None.
Insights
TL;DR: OrbiMed Capital owns a material 5.1% stake in SIBN; combined OrbiMed entities hold 6.0%.
OrbiMed Capital's reported 2,184,200 shares (5.1%) meet the common regulatory threshold for disclosure and may attract investor attention because a >5% stake signals meaningful ownership without an expressed intent to change control. The split of sole versus shared voting/dispositive power is important: OrbiMed Capital retains sole control over its 5.1% position while OrbiMed Advisors holds a smaller, shared position. The aggregate disclosure clarifies control is exercised via a management committee of three named individuals, each disclaiming beneficial ownership. This is a routine, yet material, ownership disclosure that could influence shareholder monitoring or activist interest.
TL;DR: Filing is a standard ownership disclosure with no expressed plan to alter SI-BONE's control or governance.
The Schedule 13G/A states the securities were acquired and are held in the ordinary course of business and not to change or influence control, which keeps this filing within passive/investment disclosure norms rather than an active 13D engagement. Disclosure of the management committee members and the disclaimer of beneficial ownership by those individuals provides useful governance transparency. No additional commitments, agreements, or group arrangements are reported that would indicate coordinated governance actions.
OrbiMed presenta l'Emendamento n. 5 al modulo Schedule 13G/A relativo alla partecipazione in SI-BONE, Inc. (SIBN). OrbiMed Capital LLC dichiara la titolarit脿 effettiva di 2.184.200 azioni, pari al 5,1% del capitale ordinario di SI-BONE, con pieno potere di voto e di disposizione su tali azioni. OrbiMed Advisors LLC segnala la titolarit脿 effettiva di 394.779 azioni, pari al 0,9%, con poteri di voto e disposizione condivisi. Insieme, i soggetti segnalanti detengono il 6,0% della classe per conto di altri e esercitano i poteri di investimento e di voto tramite un comitato di gestione composto da tre membri nominati. Nel deposito si afferma che le azioni sono state acquisite nell'ordinaria attivit脿 commerciale e non con l'intento di cambiare il controllo.
OrbiMed presenta la Enmienda n.潞 5 al Schedule 13G/A informando sobre su participaci贸n en SI-BONE, Inc. (SIBN). OrbiMed Capital LLC declara una propiedad beneficiaria de 2.184.200 acciones, lo que representa el 5,1% del capital social ordinario de SI-BONE, con poder exclusivo de voto y disposici贸n sobre esas acciones. OrbiMed Advisors LLC informa una propiedad beneficiaria de 394.779 acciones, equivalentes al 0,9%, con poder de voto y disposici贸n compartido. Juntos, los informantes poseen el 6,0% de la clase en nombre de otros y ejercen el poder de inversi贸n y voto a trav茅s de un comit茅 directivo formado por tres miembros nombrados. La presentaci贸n indica que las acciones se adquirieron en el curso ordinario del negocio y no con la finalidad de cambiar el control.
OrbiMed臧� SI-BONE, Inc. (SIBN) 歆�攵� 鞁犼碃毳� 鞙勴暣 Schedule 13G/A鞚� 靾橃爼靹�(Amendment No. 5)毳� 鞝滌稖頄堨姷雼堧嫟. OrbiMed Capital LLC電� 2,184,200欤茧ゼ 鞁れ 氤挫湢頃橁碃 鞛堨溂氅� 鞚措姅 SI-BONE 氤错喌欤检潣 5.1%鞐� 頃措嫻頃橁碃 頃措嫻 欤检嫕鞐� 雽�頃� 雼弲 鞚橁舶甓� 氚� 觳橂秳甓岇潉 氤挫湢頃滊嫟瓿� 氤搓碃頄堨姷雼堧嫟. OrbiMed Advisors LLC電� 394,779欤�, 歃� 0.9%毳� 鞁れ 氤挫湢頃橁碃 鞛堨溂氅� 鞚橁舶甓� 氚� 觳橂秳甓岇潉 瓿惦彊鞙茧 氤挫湢頃滊嫟瓿� 氤搓碃頄堨姷雼堧嫟. 氤搓碃鞛愲摛鞚� 頃╈硱靹� 頃措嫻 欤检嫕 韥措灅鞀れ潣 6.0%毳� 韮�鞚胳潉 雽�鞁犿暣 氤挫湢頃橁碃 鞛堨溂氅�, 歆�鞝曤悳 靹� 氇呾潣 鞙勳洂鞙茧 甑劚霅� 甏�毽渼鞗愴殞毳� 韱淀暣 韴瀽 氚� 鞚橁舶甓岇潉 頄夓偓頃╇媹雼�. 鞝滌稖靹滌棎電� 欤检嫕鞚� 鞝曥儊鞝侅澑 鞓侅梾 瓿检爼鞐愳劀 旆摑霅橃棃瓿� 歆�氚瓣秾 氤�瓴届潉 氇╈爜鞙茧 頃橃 鞎婌晿雼り碃 氇呾嫓霅橃柎 鞛堨姷雼堧嫟.
OrbiMed d茅pose l'Amendement n掳5 au Schedule 13G/A d茅clarant une participation dans SI-BONE, Inc. (SIBN). OrbiMed Capital LLC d茅clare la propri茅t茅 b茅n茅ficiaire de 2 184 200 actions, repr茅sentant 5,1% du capital ordinaire de SI-BONE, avec le pouvoir exclusif de vote et de disposition sur ces actions. OrbiMed Advisors LLC signale la propri茅t茅 b茅n茅ficiaire de 394 779 actions, soit 0,9%, avec des pouvoirs de vote et de disposition partag茅s. Ensemble, les personnes d茅clarante d茅tiennent 6,0% de la cat茅gorie au nom d'autres personnes et exercent le pouvoir d'investissement et de vote via un comit茅 de gestion compos茅 de trois membres nomm茅s. Le d茅p么t indique que les actions ont 茅t茅 acquises dans le cours normal des affaires et non dans le but de changer le contr么le.
OrbiMed reicht Nachtrag Nr. 5 zum Schedule 13G/A ein und meldet Beteiligung an SI-BONE, Inc. (SIBN). OrbiMed Capital LLC gibt an, wirtschaftlich 2.184.200 Aktien zu halten, was 5,1% des Stammkapitals von SI-BONE entspricht, und 眉ber diese Aktien alleinige Stimm- und Verf眉gungsgewalt zu besitzen. OrbiMed Advisors LLC meldet wirtschaftliches Eigentum an 394.779 Aktien, entsprechend 0,9%, mit geteilter Stimm- und Verf眉gungsgewalt. Zusammen halten die meldenden Personen 6,0% der Aktienklasse f眉r Dritte und 眉ben Anlage- und Stimmrechte durch ein Managementkomitee mit drei benannten Mitgliedern aus. In der Einreichung hei脽t es, die Aktien seien im gew枚hnlichen Gesch盲ftsverkehr erworben worden und nicht mit dem Ziel einer Macht眉bernahme.
FAQ
How many SI-BONE (SIBN) shares does OrbiMed Capital LLC report owning?
What percentage of SI-BONE does OrbiMed Advisors LLC own according to this filing?
What is the aggregate stake held by the reporting persons in SIBN?
Does the filing indicate OrbiMed intends to change or influence control of SI-BONE?
Who exercises voting power over the reported shares?
